# Paraneoplastic Cerebellar Syndrome Revealing Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Case Report

**Authors:** Sara Bendadi, Leila Afani, Othmane Zouiten, Mohamed El Fadli, Rhizlane Belbaraka

PMC · DOI: 10.7759/cureus.98519 · 2025-12-05

## TL;DR

A woman with neurological symptoms was later diagnosed with HER2-positive breast cancer, showing how rare neurological conditions can signal hidden cancers.

## Contribution

This case report links HER2-positive breast cancer with anti-Yo antibody-associated paraneoplastic cerebellar degeneration.

## Key findings

- Neurological symptoms preceded the diagnosis of HER2-positive breast cancer by two years.
- Anti-Yo antibody positivity was observed despite the absence of a cerebellar mass on MRI.
- Neurological symptoms persisted despite effective cancer treatment.

## Abstract

Paraneoplastic cerebellar degeneration (PCD) is a rare neurological disorder that can precede the diagnosis of an underlying malignancy by several months or even years. We report the case of a 46-year-old woman who presented with progressive gait instability, dysarthria, and nystagmus. Brain magnetic resonance imaging (MRI) revealed cerebellar atrophy without any mass lesion, and serologic testing showed strong anti-Yo antibody positivity. Two years later, she was diagnosed with a human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor-negative invasive ductal carcinoma of the breast. The patient underwent a modified radical mastectomy followed by adjuvant chemotherapy and trastuzumab. Despite appropriate oncologic treatment, her neurological symptoms persisted and gradually worsened. This case highlights the diagnostic challenge of PCD, particularly when neurological manifestations precede tumor detection, and suggests that HER2-positive breast cancer may also be associated with anti-Yo antibodies. Early recognition of this syndrome and systematic malignancy screening are essential to improve patient outcomes.

## Linked entities

- **Proteins:** ERBB2 (erb-b2 receptor tyrosine kinase 2)
- **Diseases:** paraneoplastic cerebellar degeneration (MONDO:0018215), breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}
- **Diseases:** Breast Cancer (MESH:D001943), dysarthria (MESH:D004401), cerebellar atrophy (MESH:D002526), mass lesion (MESH:C536030), PCD (MESH:D020362), nystagmus (MESH:D009759), gait instability (MESH:D043171), invasive ductal carcinoma of the breast (MESH:D018270), malignancy (MESH:D009369), neurological disorder (MESH:D009461)
- **Chemicals:** trastuzumab (MESH:D000068878)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12766132/full.md

---
Source: https://tomesphere.com/paper/PMC12766132